Cancer chemotherapy and biological response modifiers annual
Author(s)
Bibliographic Information
Cancer chemotherapy and biological response modifiers annual
Elsevier, c1987-
- v. 9
- v. 10
- v. 11
- v. 12
- v. 13
- v. 14
- v. 15
- v. 16
- v. 17
Available at / 11 libraries
-
Nihon University School of Medicine
v. 9M2.3||E 93||9K3000004065,
v.15M2.3||E 93||15K3000004066$, v.16M2.3||E 93||16K3000004067/, v.10M2.3||E 93||10K3000000107V, v.11M2.3||E 93||11K3000000108W, v.12M2.3||E 93||12K3000000109X, v.13M2.3||E 93||13K3000000110P, v.14M2.3||E 93||14K3000000111Q, v.17M2.3||E 93||17K3000000112R -
v. 9492.3||C15||9M00000393666,
v.10492.3||C15||10M00000393677, v.11492.3||C15||11M00000393688, v.12492.3||C15||12M00000393699, v.13492.3||C15||13M00000393701, v.14492.3||C15||14M00000393712, v.15492.3||C15||15M00000393723, v.17492.3||C15||17M00000393745, v.16492.3||C15||16M00000393734 -
No Libraries matched.
- Remove all filters.
Note
ST:Cancer chemotherapy and biological response modifiers
Includes bibliographies and indexes
In its ninth the Cancer Chemotherapy Annual series has been renamed
Description and Table of Contents
- Volume
-
v. 10 ISBN 9780444810151
Description
The year 1987 witnessed further steps in the transition from conventional chemotherapy to biological compounds for the treatment of cancer. The possibilities of the CSFs as well as the related interleukins (IL-1 and IL-3) are discussed in detail in this edition of the Annual, and represent a landmark in that the major limiting toxicity of conventional chemotherapy, myelosuppression, may become controllable and avoidable. Monoclonal antibodies and growth factor-related strategies are discussed in detail in the sections on biologicals (Chapters 28-34) and Steroid and Peptide hormones and growth factors (Chapter 11). Highlighting the progress in the understanding and clinical application of biologicals is not intended to minimize the substantial progress made in the past year in conventional chemotherapy, - including expanding indications for, and improved results of therapy with, VP-16. Considerable progress has been made in understanding MDR-1 at the biological and clinical levels in the past year (Chapter 9), whilst attention must also be drawn to the drug-related chapters providing important new information.
Table of Contents
I. DRUGS. 1. Antimetabolites (C.J. Allegra et al). 2. Alkylating agents, nitrosoureas and alkyltriazenes (T.A. Connors). 3. Anthracyclines (C.E. Myers). 4. Bleomycins (Y. Muraoka and T. Takita). 5. Mitomycin C (J. Den Hartigh et al). 6. Vinca alkaloids (G. Schwartsmann and R.A. Bender). 7. Podophyllotoxin derivatives VP-16 and VM-26 (M. D'Incalci and S. Garattini). 8. Cisplatin and new platinum analogs (L.A. Zwelling). 9. Multidrug resistance (R.L. Fine). 10. New anticancer agents (G.R. Weiss et al). 11. Steroid and peptide hormones and growth factors (A. Howell and A.E. Wakeling). II. TUMORS. 12. Leukemias and myeloma (P.H. Wiernik). 13. Lymphomas (D.L. Longo and V.T. De Vita Jr). 14. AIDS and related disorders (R. Yarchoan et al). 15. Head and neck cancer (S.G. Taylor IV). 16. Lung cancer (H.H. Hansen and M. Rorth). 17. Upper gastrointestinal tumors (M. Ogawa and T. Taguchi). 18. Cancers of the large bowel, pancreas and hepatobiliary tract (P.V. Woolley III et al). 19. Endocrine tumors (J.J.M. van der Hoeven and H.M. Pinedo). 20. Genitourinary cancer (R.F. Ozols and A. Yagoda). 21. Gynecologic malignancies (J.D. Nash and R.C. Young). 22. Breast cancer (L.C. Hartmann and C.L. Loprinzi). 23. Melanoma (Ph. Rumke). 24. Soft tissue and bone sarcomas (A. Santoro and G. Bonadonna). 25. Brain tumors (M.G. Malkin and W.R. Shapiro). 26. Pediatric tumors (D. Olive et al). 7. Supportive care (M. Markman). III. BIOLOGICAL RESPONSE MODIFIERS. 28. Monoclonal antibodies and immunoconjugates for cancer treatment (R.W. Baldwin et al). 29. Lymphokines and cytokines (J. Wagstaff and C.J. Melief). 30. Biological response modifiers (J.W. Clark). 31. Adoptive cellular therapy (W.J. Urba and D.L. Longo). 32. Immunological monitoring and clinical trials of biological response modifiers (W.J. Urba and M.W. Baseler). 33. Biological effects and clinical applications of human colony stimulating factors (J.L. Gabrilove). 34. Growth and differentiation control (G.E. Francis and C.M. Pinsky). List of abbreviations of drugs. List of abbreviations of chemotherapeutic combinations. List of NSC numbers. Subject index.
- Volume
-
v. 11 ISBN 9780444812087
Description
This Annual series provides clinicians with a systematic yearly update of current information on the clinical and experimental pharmacology of chemotherapeutic agents in the treatment of cancer. Over the past few years, the Annual series has reflected the increasing contribution of biological response modifiers to the treatment and understanding of cancer. This, the eleventh annual, covers the latest advances in this area. In addition, the development of new cytokines is covered, and the new antiretroviral drugs being developed for the treatment of AIDS included. Supportive care is highlighted, with particular reference to the remarkable results emerging from testing the value of best supportive care compared to anti-cancer treatment in various tumortypes. Advances in anti-emetic treatment are also anticipated.
Table of Contents
Introduction. I. DRUGS (10 papers). II. BIOLOGICAL RESPONSE MODIFIERS (8 papers). III. TUMORS (16 papers). Indexes.
- Volume
-
v. 12 ISBN 9780444814432
Description
In this year's annual, significant new work is described in both preclinical and clinical studies of biological and chemical agents used to treat cancer. Mechanisms of resistance to classical antitumor drugs such as methotrexate, natural products and alkylating agents can now be targeted for development of new agents and in efforts to modulate resistance in patients. In particular, transport processes appear to play key roles in models of resistance to anticancer drugs, relevant genes have been cloned and sequenced, and key proteins have been characterized. In the clinic, new active drugs, particularly taxol, have awakened great interest, and the range of uses of adjuvant regimens in node-negative breast cancer and colon cancer continues to expand. Important new biologicals, such as the bone marrow colony-stimulating factors, have won a clear role in high-dose chemotherapy regimens. Moreover, central to the effort to improve therapeutic results is the continuous and growing interplay of ideas between basic biology and clinical medicine related to cancer.
Table of Contents
Introduction. I. DRUGS 1. Antimetabolites (J.L. Grem, B.A. Chabner, E. Chu, P. Johnson, G.C. Yeh and C.J. Allegra). 2. Alkylating agents (T.A. Connors). 3. Anthracyclines (C. Myers). 4. Bleomycins (J.S. Lazo and S.M. Sebti). 5. Mitomycin C (J. Verweij and H.M. Pinedo). 6. Vinca alkaloids (B.A. Chabner, S.B. Horwitz, N.J. Clendennin and J.D. Purvis). 7. Podophyllotoxin derivatives (M. D'Incalci and S. Garattini). 8. Cisplatin (E. Reed). 9. Multidrug resistance (J.A. Moscow and K.H. Cowan). 10. New anticancer agents (T.D. Brown, H.A. Burris, K.A. Havlin, T.J. O'Rourke, G.I. Rodriguez, J.G. Wall and G.R. Weiss). II. BIOLOGICAL RESPONSE MODIFIERS 11. Monoclonal antibody therapy for cancer (D.R. Lovett, D.A. Scheinberg and A.N. Houghton). 12. Lymphokines and cytokines (J. Wagstaff). 13. Biological response modifers (J.W. Clark). 14. Adoptive cellular therapy (M. Sznol and W.J. Urba). 15. Immunological monitoring and clinical trials of biological response modifers (M.W. Baseler and W.J. Urba). 16. Growth and differentiation control (G.E. Francis and J.M. Cunningham). 17. Differentiating agents in cancer therapy (P.A. Marks and R.A. Rifkind). 18. The role of colony stimulating factors in cancer therapy (G. Morstyn and P. Sheridan). III. TUMORS 19. Leukemias and myeloma (P.H. Wiernik). 20. Lymphomas (D.L. Longo and V.T. Devita, Jr.). 21. Therapy of AIDS and AIDS-related tumors (J.M. Pluda, S. Broder and R. Yarchoan). 22. Head and neck cancer (S.G. Taylor IV). 23. Lung cancer (H.H. Hansen and M. Rorth). 24. Upper gastrointestinal tumors (M. Ogawa and T. Taguchi). 25. Cancers of the large bowel and hepatobiliary tract (J. Treat and P.V. Woolley III). 26. Endocrine tumors (S.D. Averbuch). 27. Genitourninary cancer (G.R. Hudes, R.F. Ozols and R.J. Schilder). 28. Gynecologic malignancies (J.D. Nash and R.C. Young). 29. Breast cancer (S.R. Patel and C.L. Loprinzi). 30. Malignant melanoma (J.F. Smyth). 31. Soft tissue and bone sarcomas (A. Santoro and G. Bonadonna). 32. Brain tumors (E.A. Obbens and W.R. Shapiro). 33. Pediatric malignant solid tumors (C.B. Pratt). 34. Supportive care (M. Markman). Abbreviations of drugs. Abbreviations of chemotherapeutic combinations. NSC numbers. Subject Index. Corrigendum.
- Volume
-
v. 14 ISBN 9780444815095
Description
Continuing in the tradition of the series, volume 14 covers the recent. major advances that have been made in the understanding of cancer biology, which have resulted in the development of both new classes of anti-cancer agents and new approaches to cancer treatment. The past year has witnessed varying developments, including: the interesting results produced from studies with differentiating agents, such as retinoids in acute promyolocytic leukaemia; the increase in the number of papers on new cytokines; attempts to combine IL2 with other biologicals and with cytotoxic agents in order to improve results; a better understanding between the sensitivity of hematologic malignancies and that of solid tumors; the new avenues to study dose effect relationships in cancer therapy offered by the hemopoetic growth factors GM-CSF and G-CSF- and the development of new cytotoxic ascents which interfere with newly discovered cellular pathways and mechanisms of action. Further, this year's chapters on tumors and supportive care offer many exciting new guidelines; and the chapter on the bleomycins gives excellent insight into the mechanism of pulmonary toxicity of this drug.
- Volume
-
v. 15 ISBN 9780444820563
Description
"Cancer Chemotherapy and Biological Response Modifiers" is a successful annual book series of approximately 15 years standing. Continuing in the tradition of the series, Annual 15 offers critical reviews of the recent, major developments in pharmacology of anti-cancer agents, the area of biologicals and the clinical management of the cancer patient. In 1993, new compounds continued to generate great interest, both clinically and in the laboratory. The taxanes will clearly gain important roles in the treatment of a number of solid tumors, especially breast, lung, ovarian and head and neck cancer. Similarly, the camptothecins (esp. CPT-11, topotecan), are showing interesting activity in solid tumors. The uses and pharmacology of these as well as the other new agents reviewed in this year's annual will undoubtedly become the basis of a better cancer chemotherapy in the near future. Another approach which seems promising is the use of moderately high and particularly high dose chemotherapy in solid tumors. Unfortunately, many of the reported studies are not randomized.
There is an urgent need to compare this approach with conventional chemotherapy as there are only very few clear cut indications for high dose chemotherapy. Studies which seem most relevant are upfront high dose chemotherapy compared to conventional chemotherapy in high risk testicular non-seminomas. Also, results of the Dutch and Italian randomized adjuvant chemotherapy trials in breast cancer are being awaited with great interest. Biological treatment continues to yield interesting results. Early clinical trials in the field of anti-angiogenesis, anti-invasive and anti-metastatic drugs have been initiated. New cytokines are being developed and entering the clinic as well. Altogether, medical oncology in the 1990s is developing into a most complex discipline. The reader will find each of the developments summarized by front runners in the field.
Table of Contents
- Part 1 Drugs: antimetabolites, C.J. Allegra et al
- alkylating agents, N.A. Berger
- bleomycins, J.S. Lazo
- mytomycin C, N.W. Gibson
- mitotic inhibitors, B.A. Chabner
- topoisomerase, M. D'Incalci et al
- cisplatin, E. Reed
- multidrug resistance, K.H. Cowan
- new anticancer agents, G.R. Weiss. Part 2 Biological response modifiers: monoclonal antibody, A.N. Houghton
- gene therapy, R.M. Blaese and C.A. Mullen
- biological response modifiers, J.W. Clark
- adoptive cellular, W.J. Urba
- cytokines and immunological modifiers, J.T. Holmlund
- growth and differentiation, G.E. Francis
- differentiating agents, S. Waxman
- colony stimulating, G. Morstyn et al. Part 3 Tumors: leukemias, P.H. Wiernik
- lymphomas, D.L. Longo
- head and neck cancer, S.G. Taylor
- lung cancer, H.H. Hansen
- upper gastrointestinal, M. Ogawa
- large bowel cancer, J. Treat
- endocrine cancer, S.W.J. Lamberts
- genitourinary malignancy, R.F. Ozols and G.R. Hudes
- gynecologic malignancy, R.C. Young
- breast cancer, P.P. Carbone
- melanoma, G. Schwartsmann
- tissue/bone sarcomas, A. Santoro
- brain tumors, W.R. Shapiro and E.A.M.T. Obbens
- malignant tumors, D.K. Kalwinsky
- supportive care, M. Markman.
- Volume
-
v. 16 ISBN 9780444823267
Description
Offering developments in pharmacology of anti-cancer agents, the area of biologicals and clinical management of the cancer patient, this study discusses the introduction of taxol, taxotere, gemcitabine, the topo 1 inhibitor, CTp-11 and TS such as tomudex.
- Volume
-
v. 17 ISBN 9780444826718
Description
Cancer Chemotherapy and Biological Response Modifiers has provided its readers with a comprehensive, definitive annual review of the literature in the fields of cancer biology, pharmacology, treatment and management. Its contributors are internationally renowned figures in the field of oncology. This volume contains 30 chapters reviewing recent developments within specific subject areas of oncological research. Having this up to date information on hand will ensure that you are well informed, so you can stay at the forefront of your profession.
Table of Contents
Introduction. I. DRUGS. Antimetabolites (P.G. Johnston et al.). Bleomycin (J.S. Lazo, S.M. Sebti). Mitomycins (J. Verweij). Taxanes (D. Sackett, T. Fojo). DNA topoisomerase I inhibitors (Ch.H. Takimoto, L.V. Kieffer, S.G. Arbuck). DNA topoisomerase II poisons and inhibitors (G. Capranico et al.). Cisplatin (E. Reed). Multidrug resistance (J.A. Moscow et al.). New anticancer agents (G.R. Weiss et al.). II. BIOLOGICAL RESPONSE MODIFIERS. Monoclonal antibody therapy of cancer (J.G. Jurcic, D.A. Scheinberg, A.N. Houghton). Cytokines and immunological monitoring (J.A. Sosman, A. Sawhany). Biological response modifiers (J.W. Clark). Adoptive immunotherapy (B.D. Curti). Strategies for cancer gene therapy (G. Dranoff). Retinoids, neoplasma and differentiation therapy (S.M. Lippman, P.J.A. Davies). Hematopoietic growth factors in cancer chemotherapy (G.J. Lieschke, M. Foote, G. Morstyn). III. TUMORS. Leukemias and plasma cell myeloma (P.H. Wiernik). AIDS-related malignancies (M.W. Saville). Head and neck cancer (S.G. Taylor IV). Lung cancer (H.H. Hansen, M. Rorth). Upper gastrointestinal tumors (M. Ogawa, T. Taguchi). Cancers of the large bowel and hepatobiliary tract (D.J. Vaughn, J. Treat). Endocrine tumours (S.W.J. Lamberts) Genitourinary malignancy (N. Haas, G.R. Hudes). Chemotherapy of gynecologic cancers (M.P. Boente, R. Schilder, R.Z. Ozols). Breast cancer (P.P. Carbone, H.H. Bailey, J.A. Stewart). Soft tissue and bone sarcomas (A. Santoro, P. Casali). Brain tumors (E.A.M.T. Obbens, W.R. Shapiro). Biology and treatment of pediatric malignant solid tumors (N.M. Marina). Supportive care (M. Markman). Abbreviations of drugs. Abbreviations of chemotherapeutic combinations. Biological abbreviations. NSC-numbers. Subject index.
- Volume
-
v. 13 ISBN 9780444896834
Description
Several extremely interesting new developments have taken place in clinical cancer research in the past year. Cellular pharmacology of anti-neoplastic agents has continued gathering momentum. More insight has been acquired into the mechanisms of drug resistance where multi-drug resistance (MDR) is the center of interest. It is important in this research to define clinical resistance at the cellular level by using tumor biopsies from patients sensitive or resistant to chemotherapy and MDR reverters. The use of high-dose chemotherapy, as another approach to overcoming drug resistance is proving to be quite successful in lymphomas and is now being tested in chemosensitive tumors. Major emphasis has been put on improving the tolerability of high-dose chemotherapy. G-CSF and GM-CSF have allowed the possibility of delivering significantly higher doses of chemotherapy, achieving higher complete remission rates. Several studies are also investigating the potential role of G-CSF and GM-CSF in myelodisplastic syndromes. The finding that differentiating agents like retinoids are capable of inducing remissions in acute promyelocytic leukemia is extremely exciting.
Table of Contents
Introduction. I. DRUGS 1. Antimetabolites (E. Chu, et al.). 2. Alkylating agents (T.A. Connors). 3. Anthracyclines (C.E. Myers). 4. Bleomycins (J.S. Lazo, S.M. Sebti). 5. Mitomycin C (N.W. Gibson, D. Siegel, D. Ross). 6. Mitotic inhibitors (B.A. Chabner). 7. Podophyllotoxin derivatives (M. D'Incalci, S. Garattini). 8. Cisplatin (E. Reed). 9. Multidrug resistance (J.A. Moscow, C.S. Morrow, K.H. Cowan). 10. New anticancer agents (T.D. Brown, et al.). II. BIOLOGICAL RESPONSE MODIFIERS 11. Monoclonal antibody therapy (M. Schwartz, D.A. Scheinberg, A.N. Houghton). 12. Biological response modifiers (J.W. Clark). 13. Adoptive cellular therapy (M. Sznol, W.J. Urba). 14. Immunological monitoring and clinical trials of biological response modifiers (M.W. Baseler, W.J. Urba). 15. Growth and differentiation control (G.E. Francis, M. Domine). 16. Differentiating agents in cancer therapy (J. Michaeli, R.A. Rifkind, P.A. Marks). 17. Colony-stimulating factors in cancer therapy (G. Morstyn, W.P. Sheridan). III. TUMORS. 18. Leukemias and plasma cell myeloma (P.H. Wiernik). 19. Lymphomas (D.L. Longo, V.T. DeVita, Jr.). 20. Therapy of AIDS and AIDS-associated neoplasms (J.M. Pluda, S. Broder, R. Yarchoan). 21. Head and neck cancer (S.G. Taylor IV). 22. Lung cancer (H.H. Hansen, M. Rorth). 23. Upper gastrointestinal tumors (M. Ogawa, T. Tagushi). 24. Cancers of the large bowel and hepatobiliary tract (J. Treat, P.V. Woolley III). 25. Endocrine tumors (S.D. Averbuch). 26. Genitourinary cancer (G.R. Hudes, et al.). 27. Gynecological malignancies (R.J. Schilder, S.A. Godfrey, R.C. Young). 28. Breast cancer (H.C. Pitot, C.L. Loprinzi). 29. Malignant melanoma (J.F. Smyth). 30. Soft tissue and bone sarcomas (A. Santoro, G. Bonadonna). 31. Brain tumors (E.A.M.T. Obbens, W.R. Shapiro). 32. Childhood solid tumors (C.B. Pratt). 33. Supportive care (M. Markman). Abbreviations of drugs. Abbreviations of chemotherapeutic combinations. Biological Abbreviations. NSC numbers. Subject index.
- Volume
-
v. 9 ISBN 9780444904850
Description
In its ninth year the Cancer Chemotherapy Annual series has been renamed, reformatted and expanded to include a section on biological response modifiers. It is, and will remain, the only medium for oncologists to keep pace with the many thousands of articles published in their field. The international board of some seventy contributors now also includes experts in biological therapeutics, who have evaluated their segment of the international medical literature. The editors, H.M. Pinedo and B.A. Chabner, have secured the assistance of D.L. Longo, who qualifies as the director of the Biological Response Modifiers Program of the National Cancer Institute in Frederick, MD, USA.
Table of Contents
Introduction (H.M. Pinedo and B.A. Chabner). I. DRUGS. 1. Antimetabolites (C.J. Allegra, J. Baram, B.A. Chabner, G.C. Yeh, K. Aiba and G.A. Curt). 2. Alkylating agents, nitrosoureas and alkyltriazenes (T.A. Connors). 3. The anthracyclines (C. Myers). 4. Bleomycins (Y. Muraoka and T. Takita). 5. Mitomycin C (J. den Hartigh, J. Verweij and H.M. Pinedo). 6. Vinca alkaloids (R.A. Bender). 7. Podophyllotoxin derivatives VP-16 and VM-26 (M. D'Incalci and S. Garattini). 8. Cisplatin and new platinum analogs (L.A. Zwelling). 9. Multidrug resistance (R.L. Fine and B.A. Chabner). 10. New anticancer agents (G.R. Weiss, C.L. Arteaga, T.D. Brown, J.B. Craig, G.S. Harman, J.M. Koeller, J.G. Kuhn and D.D. Von Hoff). 11. Steroid and peptide hormones and growth factors (A. Howell and A.E. Wakeling). II. TUMORS. 12. Leukemia and myelomatosis (D. Catovsky). 13. Lymphomas (D.L. Longo and V.T. DeVita). 14. Therapy of acquired immunodeficiency syndrome (R. Yarchoan, H. Masur and S. Broder). 15. Head and neck cancer (S.G. Taylor IV). 16. Lung cancer (H.H. Hansen and M. Rorth). 17. Upper gastrointestinal tumors (M. Ogawa and T. Taguchi). 18. Cancers of the large bowel and hepatobiliary system (J.A. Treat, J.D. Ahlgren and P.V. Woolley). 19. Endocrine tumors (J.J.M. van der Hoeven and P.S. Schein). 20. Genitourinary cancer (R.F. Ozols and A. Yagoda). 21. Gynecologic malignancies (R.C. Young). 22. Breast cancer (C.L. Loprinzi and P.P. Carbone). 23. Melanoma (Ph. Rumke). 24. Soft tissue and bone sarcomas (A. Santoro and G. Bonadonna). 25. Brain tumors (M.G. Malkin and W.R. Shapiro). 26. Pediatric tumors (D. Olive, E. Benz-Lemoine and P. Bey). 27. Supportive care (M. Markman). III. BIOLOGICAL RESPONSE MODIFIERS. 28. Monoclonal antibodies and immunoconjugates for cancer treatment (R.W. Baldwin and V.S. Byers). 29. Lymphokines and cytokines (J. Wagstaff and C.J. Melief). 30. Biological response modifiers: preclinical and clinical results (J.E. Talmadge and J. Clark). 31. Adoptive cellular therapy (W.J. Urba and D.L. Longo). 32. Strategies for immunological monitoring (W.J. Urba, A.E. Maluish and D.L. Longo). 33. Growth and differentiation control (G.E. Francis and C. Pinsky). List of abreviations of drugs. List of abbreviations of chemotherapeutic combinations. List of NSC numbers. Subject index (prepared by H. Kettner).
by "Nielsen BookData"
